Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Entry into a Material Definitive Agreement

Foundation Medicine, Inc. (NASDAQ:FMI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

On September8, 2017, the Company and Roche entered into a Fifth Amendment (“Amendment”) to the Collaboration Agreement, by and among the Company, F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc., dated January11, 2015, as amended (the “R&D Collaboration Agreement”), which reduced certain exclusivity provisions relating to blood-based tumor mutational burden assays.

The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated herein by reference, and by reference to the full text of the R&D Collaboration Agreement, which was attached as Exhibit 10.2 to the Company’s Current Report on Form 8-K/A filed on August21, 2015.

Item 1.01. Financial Statements and Exhibits.

(d) Exhibits


Foundation Medicine, Inc. Exhibit
EX-10.1 2 d413862dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 FIFTH AMENDMENT TO COLLABORATION AGREEMENT This Fifth Amendment (“Fifth Amendment”) to the Collaboration Agreement (the “Agreement”) by and between F. Hoffmann-La Roche Ltd,…
To view the full exhibit click here

About Foundation Medicine, Inc. (NASDAQ:FMI)

Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer. Its other products include FoundationACT (Assay for Circulating Tumor deoxyribonucleic acid (DNA)), GeneKit, FoundationCORE, FoundationICE and the SmartTrials program.

Foundation Medicine, Inc. (NASDAQ:FMI) Recent Trading Information

Foundation Medicine, Inc. (NASDAQ:FMI) closed its last trading session up +0.50 at 41.10 with 77,465 shares trading hands.

An ad to help with our costs